 | 紅榮微再（上海）生物工程技術(shù)有限公司 |
15021010459
在線溝通：
顏先生 （銷售）
- 電話：
- 400-021-2200
- 手機：
- 15021010459
- 傳真：
- 聯(lián)系我時，
- 告知來自化工儀器網(wǎng)
- 個性化：
- www.hyrmb.com.cn
- 商鋪網(wǎng)址：
- http://www.syzwkj.com/st321032/
- 公司網(wǎng)站：
- www.hyrmb.com
液體活檢：外周血游離循環(huán)腫瘤細胞（CTC）保存管
閱讀：4840發(fā)布時間：2018-1-26
腫瘤CTC介紹
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy,
Catherine Alix-Panabières,Cancer Discov;6(5); 479–91. ©2016 AACR Published OnlineFirst March 11, 2016; DOI: 10.1158/2159-8290.CD-15-1483.
原發(fā)腫瘤（乳房、結(jié)腸、肺、前列腺癌）在形成生長早期，會釋放細胞進入血液循環(huán)。通過各種技術(shù)可以富集檢測這些循環(huán)腫瘤細胞的物理和生物性質(zhì)。
循環(huán)腫瘤細胞，Circulating Tumor cell，簡稱CTC。CTC釋放點：原發(fā)腫瘤和轉(zhuǎn)移腫瘤。
CTC死亡后還會釋放出循環(huán)腫瘤DNA，Circulating Tumor DNA，簡稱ctDNA。
CTC和ctDNA的臨床應(yīng)用
腫瘤檢測 CTCs和ctDNA應(yīng)用腫瘤的早期檢測很受關(guān)注，面臨的挑戰(zhàn)是目前分析的特定性和敏感度。
預(yù)后評估 多種腫瘤已經(jīng)實現(xiàn)預(yù)后評估，尤其是乳癌。
指導(dǎo)系統(tǒng)治療
病人亞群分類（stratification）。
外周血游離循環(huán)腫瘤細胞（CTC）保存管
——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管內(nèi)含特殊保護劑，可以保護循環(huán)腫瘤細胞，常溫下可以保存CTC達7天。
英文名稱：Streck Cell-Free DNA BCT® BLOOD COLLECTION TUBE
中文名稱：Streck BCT® 血漿游離DNA采血/保存管
貨號：218962,230253
Streck 血漿游離DNA采血管是一種直接提取的全血收集管，用于收集、運輸和儲存血液樣本。Streck 血漿游離DNA采血管內(nèi)含防腐劑，它能穩(wěn)定有核血細胞，防止細胞基因組DNA的釋放，保護血漿游離循環(huán)DNA和循環(huán)腫瘤細胞（CTC）。
230253是Streck Cell-Free DNA BCT® 10mL采血管218962的升級版，是Streck公司新推將玻璃和塑料的*性能融合在一起的Fusion2TM混合塑料管。
Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管應(yīng)用
NIPT無創(chuàng)產(chǎn)前檢測：孕婦外周血的胎兒游離DNA保存
腫瘤液體活檢：循環(huán)腫瘤細胞（CTCs）和ctDNA（循環(huán)腫瘤DNA）保存
其他：血漿基因組DNA和游離DNA保存
Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管基因保存性能
游離DNA、細胞內(nèi)基因組DNA和循環(huán)腫瘤細胞樣本保存/穩(wěn)定性
樣本類型 | 游離DNA | 胞內(nèi)基因組DNA | 腫瘤細胞（上皮細胞） |
樣本保存時間 | 14天 | 14天 | 7天 |
樣本保存溫度 | 6-37℃ | 6-37℃ | 15-30℃ |
Streck 218962（現(xiàn)貨）,230253 Cell-Free DNA BCT采血管歡迎您咨詢華雅再生醫(yī)學(xué)旗艦公司：紅榮微再（上海）生物工程技術(shù)有限公司 ：1500 1904 520。紅榮微再-客服: 2395557778 經(jīng)銷商專員。
外周血游離循環(huán)腫瘤細胞（CTC）保存管
——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管
文獻使用Circulating Tumor Cells (CTCs)
Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival
Boffa D.J., Graf R.P., Salazar M.C., Hoag J., Lu D., Krupa R., et al.
Cancer Epidemiology, Biomarkers & Prevention, 2017.
Chromosomal instability estimation based on next generation sequencing and single cell genome wide copy number variation analysis
Greene S.B., Dago A.E., Leitz L.J., Wang Y., Lee J., Werner S.L., et al.
PLoS One, 2016.
Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples
Gogoi P., Sepehri S., Zhou Y., Gorin M.A., Paolillo C., Capoluongo E., et al.
PLoS One, 2016.
Detection and characterization of circulating tumour cells in multiple myeloma
Zhang L., Beasley S., Prigozhina N.L., Higgins R., Ikeda S., Lee F., et al.
Journal of Circulating Biomarkers, 2016.
Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
Scher H.I., Lu D., Schreiber N.A., Louw J., Graf R., Vragas H.A., et al.
Journal of the American Medical Association Oncology, 2016.
A novel approach for next-generation sequencing of circulating tumor cells
Yee S.S., Lieberman D.B., Blanchard T., Rader J., Zhao J., Troxel, A.B., et al.
Molecular Genetics & Genomic Medicine, 2016.
Analytical validation and capabilities of the Epic CTC platform: enrichment-free circulating tumour cell detection and characterization
Werner S.L., Graf R.P., Landers M., Valenta D.T., Schroeder M., Greene S.B., et al.
Journal of Circulating Biomarkers, 2015.
Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction
Bethel K., Luttgen M.S., Damani S., Kolatkar A., Lamy R., Sabouri-Ghomi M., et al.
Physical Biology, 2014.
Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer
Chudziak J., Burt D.J., Mohan S., Rothwell D.G., Mesquita B., Antonello J., et al.
Analyst, 2015.
Detection and characterization of circulating tumour cells from frozen peripheral blood mononuclear cells
Lu D., Graf R.P., Harvey M., Madan R.A., Heery C., Marte J., et al.
Journal of Circulating Biomarkers, 2015.
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients
Ruiz C., Li J., Luttgen M.S., Kolatkar A., Kendall J.T., Flores E., et al.
Physical Biology, 2015.
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
Punnoose E.A., Ferraldeschi R., Szafer-Glusman E., Tucker E.K., Mohan S., Flohr P., et al.
British Journal of Cancer, 2015.
Rapid changes in circulating tumor cells following anti-angiogenic therapy
Gross M.E., Dorff T.B., Quinn D.I., Agus D.B., Luttgen M., Bethel K., et al.
Convergent Science Physcial Oncology, 2015.
Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer
Carlsson A., Nair V.S., Luttgen M.S., Keu K.V., Horng G., Vasanawala M., et al.
Journal of Thoracic Oncology, 2014.
An observational study of circulating tumor cells and 18F-FDG PET uptake in patients with treatment-naïve non-small cell lung cancer
Nair V.S., Keu K.V., Luttgen M.S., Kolatkar A., Vasanawala M., Kuscher W., et al.
PLoS One, 2013.
Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient
Phillips K.G., Velasco C.R., Li J., Kolatkar A., Luttgen M., Bethel K., et al.
Frontiers in Oncology, 2012.
Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient
Phillips K.G., Kolatkar A., Rees K.J., Rigg R., Marrinucci D., Luttgen M., et al.
Frontiers in Oncology, 2012.
Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/ inflammatory, and stage IV breast cancer, using a novel detection technology
Somlo G., Lau S.K., Frankel P., Hsieh H.B., Liu X., Yang L., et al. Breast Cancer Research and Treatment, 2011.
Cytomorphology of circulating colorectal tumor cells: a small case series
Marrinucci D., Bethel K., Lazar D., Fisher J., Huynh E., Clark P., et al.
Journal of Oncology, 2010.
Sensitive characterization of circulating tumor cells for improving therapy selection
Hsieh H.B., Somlo G., Bennis R., Frankel P., Krivacic R.T., Lau S., et al.
SBEC, 2010, IFMBE Proceedings 32.
外周血游離循環(huán)腫瘤細胞（CTC）保存管
——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管
訂購信息
品牌 | 貨號 | 產(chǎn)品描述 | 包裝 |
Streck | 218962 | Cell-Free DNA BCT® BLOOD COLLECTION TUBE Cell-Free DNA BCT®血漿游離DNA采血管 | 100管/盒 |
Streck | 230253 | Cell-Free DNA BCT® BLOOD COLLECTION TUBE Cell-Free DNA BCT®血漿游離DNA采血管（混合塑料） | 100管/盒 |
外周血游離循環(huán)腫瘤細胞（CTC）保存管
Streck 218962（現(xiàn)貨）,230253 Cell-Free DNA BCT采血管及更多液體活檢產(chǎn)品歡迎您咨詢華雅再生醫(yī)學(xué)旗艦公司：紅榮微再（上海）生物工程技術(shù)有限公司 ：1500 1904 520。紅榮微再-客服: 2395557778 經(jīng)銷商專員。紅榮微再以“傳遞科學(xué)價值，服務(wù)科學(xué)研究”為宗旨，主營干細胞、醫(yī)療、細胞治療、器官再生四大板塊的產(chǎn)品。
以上信息由企業(yè)自行提供，信息內(nèi)容的真實性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負責(zé)，化工儀器網(wǎng)對此不承擔(dān)任何保證責(zé)任。 溫馨提示：為規(guī)避購買風(fēng)險，建議您在購買產(chǎn)品前務(wù)必確認供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。